These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14969457)

  • 21. Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction.
    Banov MD
    J Clin Psychiatry; 1999 Dec; 60(12):866-8. PubMed ID: 10665636
    [No Abstract]   [Full Text] [Related]  

  • 22. Generalized estimating equations for ordinal data: a note on working correlation structures.
    Lumley T
    Biometrics; 1996 Mar; 52(1):354-61. PubMed ID: 8934602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
    Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deliberate self-poisoning following fluvoxamine-neuroleptics combination.
    Chong SA; Cheong A
    J Clin Psychiatry; 1999 Dec; 60(12):869. PubMed ID: 10665638
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 27. Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine.
    Stirnimann G; Petitprez S; Abriel H; Schwick NG
    Europace; 2010 Feb; 12(2):282-3. PubMed ID: 19875396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin syndrome induced by fluvoxamine and oxycodone.
    Karunatilake H; Buckley NA
    Ann Pharmacother; 2006 Jan; 40(1):155-7. PubMed ID: 16368927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling multivariate discrete failure time data.
    Shih JH
    Biometrics; 1998 Sep; 54(3):1115-28. PubMed ID: 9750256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling longitudinal data with ordinal response by varying coefficients.
    Kauermann G
    Biometrics; 2000 Sep; 56(3):692-8. PubMed ID: 10985204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.
    Rinne T; van den Brink W; Wouters L; van Dyck R
    Am J Psychiatry; 2002 Dec; 159(12):2048-54. PubMed ID: 12450955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
    Silver H; Nassar A; Aharon N; Kaplan A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects.
    Menting JE; Honig A; Verhey FR; Hartmans M; Rozendaal N; de Vet HC; van Praag HM
    Int Clin Psychopharmacol; 1996 Sep; 11(3):165-75. PubMed ID: 8923095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding.
    Gentile S
    Arch Womens Ment Health; 2006 May; 9(3):158-9. PubMed ID: 16683078
    [No Abstract]   [Full Text] [Related]  

  • 35. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease.
    Gönül AS; Aksu M
    J Clin Psychiatry; 1999 Jun; 60(6):410. PubMed ID: 10401924
    [No Abstract]   [Full Text] [Related]  

  • 36. Marginalized transition models and likelihood inference for longitudinal categorical data.
    Heagerty PJ
    Biometrics; 2002 Jun; 58(2):342-51. PubMed ID: 12071407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine.
    Kohn Y; Weizman A; Apter A
    Int J Eat Disord; 2001 Jul; 30(1):113-7. PubMed ID: 11439417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of fluvoxamine-mediated long QTU syndrome.
    Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F
    Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.